Claims

1. Use of a pharmaceutical composition comprising a first analgesic agent in an amount of 5 mg to 2000 mg selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen in the manufacture of a medicament for reducing the frequency of urination, wherein said pharmaceutical composition is formulated for immediate-release, delayed-release, extended-release or combinations thereof.

2. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for immediate-release.

3. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

4. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for extended-release.

5. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for a combination of immediate-release and extended-release.

6. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation by embedding said first ingredient in a matrix of insoluble substance(s).

7. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a polymer controlling release by dissolution controlled release.

8. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a water soluble or water-swellable matrix-forming polymer.

9. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is coated with an enteric coating.

10. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises a second analgesic agent in the amount of 5 mg to 2000 mg selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, wherein said second analgesic agent is different from said first analgesic agent.

11. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for immediate-release.

12. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for delayed-release.

13. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for extended-release.

14. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for a combination of immediate-release and extended-release.

15. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

16. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises one or more antidiuretic agents.

17. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises one or more spasmolytics.

18. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is administered after the administration of a diuretic, wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.

19. Use of the pharmaceutical composition comprising a first component formulated for immediate-release and a second component formulated for extended-release in the manufacture of a medicament for reducing the frequency of urination, wherein said first component and said second component each comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein each analgesic agent in said first component and said second component is present in an amount of 5 mg to 2000 mg.

20. The use of the pharmaceutical composition of Claim 19, wherein said second component is coated with an enteric coating.

21. The use of the pharmaceutical composition of Claim 19, wherein each of said analgesic agent is present in an amount of 50 mg to 500 mg.

22. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

23. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises an antidiuretic agent.

24. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises one or more spasmolytics.

25. The use of the pharmaceutical composition of Claim 19, wherein said pharmaceutical composition is administered after the administration of a diuretic, wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.

26. A pharmaceutical composition, comprising:

one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen;

an antidiuretic agent; and

a pharmaceutically acceptable carrier,

wherein said pharmaceutical composition is formulated for extended-release in an oral dosage form, and wherein the total dosage of said one or more analgesic agents is 5 mg to 1000 mg.

27. The pharmaceutical composition of Claim 26, further comprising an antimuscarinic agent.

28. The pharmaceutical composition of Claim 26, further comprising a spasmolytic.

29. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is in a liquid or solid formulation.

30. The pharmaceutical composition of Claim 26, wherein said pharmaceutical composition is in a liquid or solid formulation.

Claims

1. Use of a pharmaceutical composition comprising a first analgesic agent in an amount of 5 mg to 2000 mg acetaminophen in the manufacture of a medicament for reducing the frequency of urination in nocturia in a subject in need thereof, wherein said pharmaceutical composition is formulated for immediate-release, delayed-release, extended-release or combinations thereof.

2. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for immediate-release.

3. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

4. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for extended-release.

5. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for a combination of immediate-release and extended-release.

6. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation by embedding said first ingredient in a matrix of insoluble substance(s).

7. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a polymer controlling release by dissolution controlled release.

8. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a water soluble or water-swellable matrix-forming polymer.

9. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is coated with an enteric coating.

10. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises a second analgesic agent in the amount of 5 mg to 2000 mg selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, and nabumetone.

11. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for immediate-release.

12. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for delayed-release.

13. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for extended-release.

14. The use of the pharmaceutical composition of Claim 10, wherein said pharmaceutical composition is formulated for a combination of immediate-release and extended-release.

15. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

16. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises one or more antidiuretic agents.

17. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition further comprises one or more spasmolytics.

18. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is administered after the administration of a diuretic, wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.

19. Use of the pharmaceutical composition comprising a first component formulated for immediate-release and a second component formulated for extended-release in the manufacture of a medicament for reducing the frequency of urination in nocturia in a subject in need thereof, wherein said first component comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen and said second component is acetaminophen, and wherein each analgesic agent in said first component and said second component is present in an amount of 5 mg to 2000 mg.

20. The use of the pharmaceutical composition of Claim 19, wherein said second component is coated with an enteric coating.

21. The use of the pharmaceutical composition of Claim 19, wherein each of said analgesic agent is present in an amount of 50 mg to 500 mg.

22. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

23. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises an antidiuretic agent.

24. The use of the pharmaceutical composition of Claim 19, wherein said first component and/or said second component further comprises one or more spasmolytics.

25. The use of the pharmaceutical composition of Claim 19, wherein said pharmaceutical composition is administered after the administration of a diuretic, wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.

26. A pharmaceutical composition, comprising:
acetaminophen;
an antidiuretic agent; and
a pharmaceutically acceptable carrier,
wherein said pharmaceutical composition is formulated for extended-release in an oral dosage form, and wherein the total dosage of said one or more analgesic agents is 5 mg to 1000 mg.

27. The pharmaceutical composition of Claim 26, further comprising an antimuscarinic agent.

28. The pharmaceutical composition of Claim 26, further comprising a spasmolytic.

29. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is in a liquid or solid formulation.

30. The pharmaceutical composition of Claim 26, wherein said pharmaceutical composition is in a liquid or solid formulation.